###### Strength and limitation of this study

-   This review only included prospective and retrospective observational studies that derived objective prescription claim data from outside clinical trial settings, to better reflect real-world adherence and persistence to oral bisphosphonates for the treatment of osteoporosis.

-   This review was able to derive persistence and adherence data from 89 observational studies performed within 15 different countries,

-   The calculation of persistence and adherence across the included studies were heterogeneous. As a result, it was not possible to directly compare these studies via meta-analysis.

-   The review did not collect self-reported patient data. This data may have given further insight as to the determinants of persistence and adherence among patients with osteoporosis.

Introduction {#s1}
============

Osteoporosis is a chronic global health condition, characterised by low bone density and bone structure deterioration.[@R1] About a third of men and more than half of all women experience osteoporosis during their lives.[@R2] Moreover, evidence suggests that fracture-related mortality rate is higher in men than women.[@R3] The first sign of osteoporosis is often a fracture of the wrist, hip and spine. Osteoporotic fractures can lead to long-term problems such as chronic pain, long-term disability and even death.[@R4] The long-term problems of osteoporosis may also lead to a substantial economic burden on individuals, health systems and society. Osteoporosis is a common disease in the USA, and more than 1.5 million osteoporosis-related fractures occur each year.[@R5] For example, the findings of a study of osteoporosis-related fractures in the USA indicated that patients with a diagnosis of osteoporosis and concurrent fracture (\$15,942) had more than two times the annual healthcare expenditure, compared with patients with osteoporosis without a fracture (\$6,476).[@R5] The total cost estimates for the treatment of osteoporosis and subsequent care in the USA was around \$17 billion in 2003 and this is expected to increase by 50% in 2025.[@R6] The majority of this cost is spent on acute surgical and medical management, and subsequent rehabilitation.[@R6]

Bisphosphonate medications for osteoporosis have been shown to increase bone strength and reduce fracture risk and can be administered orally or intravenously across a wide range of doses and dosing intervals.[@R8] Bisphosphonate treatments such as etidronate, alendronate, ibandronate, risedronate and zoledronic acid are able to prevent vertebral fractures more than placebo.[@R10] Prevention can be classified as primary or secondary. Primary prevention attempts to protect individuals against the onset of osteoporosis, whereas secondary prevention treats individuals living with the disease.[@R11] Treatments such as alendronate, risedronate and other oral medications such as oestrogen can prevent hip fractures more than placebo. Patients treated with alendronate and zoledronic acid had better efficacy in preventing hip fracture. On the other hand, zoledronic acid was reported to lead to an increased risk of adverse events than alendronate and placebo.[@R12] The clinical issues that should be considered when treating patients with osteoporosis using bisphosphonates include: the choice of which type of bisphosphonates to use, monitoring to assure the medication is taken correctly, determining the time when these medications should be discontinued and the management of their side effects.[@R13]

Patient persistence and adherence to oral bisphosphonates can be assessed using real-world data. This can be derived from electronic health records, product and disease registries, claims and billing data and data gathered through personal devices.[@R14] The International Society for Pharmacoeconomics and Outcomes Research defines persistence as the accumulation of time from initiation to discontinuation of therapy.[@R15] Adherence/compliance was defined as the extent to which a patient acts in accordance with the prescribed interval and dose as well as dosing regimen. Poor persistence and adherence to bisphosphonate therapy can significantly increase the risk of fracture and overall burden of osteoporosis.[@R12] Thus it is important to quantify the prevalence of this in wider populations and consider potential factors that may influence this, such as patient characteristics.

Although previous systematic reviews have included some real-world data, the studies were not assessed for quality and did not examine the potential determinants of adherence and persistence.[@R16] To the authors' knowledge, there is no contemporary review that focuses on oral bisphosphonate medication adherence and persistence among patients with osteoporosis in the realworld. Understanding patient persistence and adherence to oral bisphosphonates and their determinants may be used to reduce the risk of fractures in the treatment of osteoporosis.[@R1] Therefore, this current systematic review addresses two objectives. First, it summarises patient persistence and adherence to oral bisphosphonates in real-world settings. Second, it identifies determinants that may affect real-world adherence and persistence.

Methods {#s2}
=======

This systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline, a technique that addresses the eligibility, data sources, selection of studies, data extraction and data analysis.[@R18] The review was registered on PROSPERO, with registration number CRD: 42017059894.

Data sources {#s2a}
------------

We searched the Allied and Complementary Medicine Database, Cumulative Index to Nursing and Allied Health Literature, MEDLINE; Database of Abstracts of Reviews of Effects, Health Technology Assessment database and the Centre for Reviews and Dissemination database up to April 2018. The search terms used were persist\* OR adher\* OR non-adher\* OR complian\* OR discontinu\* OR prescri\* OR pattern\* OR gap\* (TITLE) AND Osteoporo\* OR Osteopen\* OR (Bone AND loss) OR Alendron\* OR Etidron\* OR Ibandron\* OR Risedron\* OR bisphosphonat\* (TITLE). All search results were exported into EndNote Web (Thomas Reuter, CA, USA) bibliography software.

Inclusion criteria {#s2b}
------------------

Prospective and retrospective observational studies that used prescription claims databases or patient electronic medical records or to investigate persistence and adherence to oral bisphosphonate medications in the treatment of osteoporosis or osteopenia in human adults were included. Eligible studies were required to have an abstract and article published in the English language, within a peer-reviewed source. Studies conducted in any geographical location were permitted. Randomised controlled trials (RCTs), systematic reviews, narrative literature reviews and conference papers were excluded. Further exclusion criteria were as follows; abstract unavailable, studies not yet fully completed, single case studies/reports, observational studies drawing persistence/adherence data from patient or general practitioner survey, prospective studies designed to observe changes in adherence via the introduction of a non-typical intervention or adjunct and studies containing patients aged \<18 years.

Study selection {#s2c}
---------------

Duplicates were removed electronically and manually. Two independent researchers (PS and TG) were involved in screening the title and abstract of each study. Full-text articles were obtained and were excluded if they did not meet the inclusion criteria. Any disagreement in study selection was resolved through discussion and consultation with other members of the project team (GY and FF), where necessary. During screening, open-label extension studies of RCTs were excluded. It was considered that this design may not generate data that truly reflected a real-world pattern of persistence and adherence. Studies using data from electronic medical records, outside of addition to large-scale databases were also included provided persistence and adherence data were determined from prescription claims data rather than extracted from supplemental patient interviews, patient-supplied pill counts or subjective questionnaires. The literature search was supplemented by screening the reference lists of included articles for further eligible studies.

Data extraction and study quality assessment {#s2d}
--------------------------------------------

Determinants (factors that may affect or be associated with) persistence or adherence were extracted from eligible studies, including patient characteristics such as age and sex, medication, population location, time-frame of data collection and length of follow-up. The quality of the studies was assessed using the Newcastle--Ottawa quality assessment scale (NOS) for cohort studies.[@R19] The NOS contains eight items, categorised into three dimensions including selection and comparability. The maximum score of NOS is nine. However, some questions within the NOS were not applicable across the eligible studies dependent on their study design. In this instance, authors determined and adjusted the NOS score to account for this, rating studies only on the number of questions that were applicable and relevant.

Data analysis {#s2e}
-------------

A descriptive analysis of extracted results is presented. No meta-analysis was carried out due to heterogeneity of reporting methodologies and calculations of adherence and persistence across studies.

Patient and public involvement {#s2f}
------------------------------

Patients and the general public were not involved in this study.

Results {#s3}
=======

The literature search identified 540 potential articles, of which 517 were remained after the removal of duplicates. After the titles and abstracts of these publications were screened, 143 references were identified as potentially relevant and retrieved in full text. Of these, 89 were included in review ([figure 1](#F1){ref-type="fig"}). The methodological quality of the included studies is presented ([table 1](#T1){ref-type="table"}). All the included studies scored between six to eight on the NOS.

![The preferred reporting for systematic reviews and meta-analyses diagram representing the systematic literature search.[@R94]](bmjopen-2018-027049f01){#F1}

###### 

Summary of studies included in this review

  Reference                          Type of database                                                                                                                               Country       Time frame of data collection   Length of follow-up   Adjusted NOS scores
  ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------------------- --------------------- ---------------------
  Abrahamsen[@R29]                   National prescription                                                                                                                          Denmark       1995 to 2007                    10 years              6/6
  Blouin *et al* [@R30]              Régie de l'asssurance maladie du Québec                                                                                                        Canada        2002to 2004                     2 years               8/8
  Blouin *et al* [@R20]              Régie de l'asssurance maladie du Québec                                                                                                        Canada        1998 to 2001 & 2000 to 2004     1 year                6/6
  Brankin *et al* [@R31]             General practice research database IMS disease analyser                                                                                        UK            2001 to 2004                    1 year                6/6
                                     Doctors independent network database                                                                                                                                                                               
  Briesacher *et al* [@R32]          MarketScan research databases                                                                                                                  USA           2000 to 2004                    1 to 3 years          6/6
  Briesacher *et al* [@R33]          MarketScan commercial claims and encounters and Medicare                                                                                       N/A           2001 to 2006                    1 year                6/6
  Burden *et al* [@R34]              Ontario drug benefit database                                                                                                                  Canada        1996 to 2009                    1 to 9 years          6/6
  Burden *et al* [@R35]              Ontario drug benefit database                                                                                                                  Canada        2001 to 2012                    1 year                6/6
  Cadarette *et al* [@R21]           Pennsylvania pharmaceutical assistance contract                                                                                                USA           1995 to 2005                    6 months              6/6
  Carbonell-Abella *et al* [@R22]    Sistema d'informacio per al desenvolupament de la investigacio en atencio primaria                                                             Spain         2007 to 2010                    1 year                8/8
  Cheen *et al* [@R36]               CITRIX patient record management system and MAXCARE prescription record system, Singapore General Hospital                                     Singapore     2007 to 2008                    2 years               6/6
  Cheng *et al* [@R23]               Chang-Gung Memorial Hospital, Kaohsiung Medical Centre                                                                                         Taiwan        2001 to 2007                    2 years               8/8
  Colombo and Montecucco[@R37]       Aziende sanitarie locali                                                                                                                       Italy         2008 to 2008                    34 months             6/6
  Copher *et al* [@R38]              Administrative claims                                                                                                                          USA           2002 to 2006                    1 year                8/8
  Cotté *et al* [@R39]               Thales longitudinal prescription                                                                                                               France        2007 to 2008                    1 year                8/8
  Cramer *et al* [@R40]              De-identified healthcare claims                                                                                                                USA           1997 to 2002                    1 year                8/8
  Cramer *et al* [@R41]              Integrated Healthcare Information Services Inc.                                                                                                USA           1997 to 2003                    1 year                6/6
                                     General practice research database                                                                                                             UK            2001 to 2005                                          
                                     Thales                                                                                                                                         France        2000 to 2004                                          8/8
  Curtis *et al* [@R42]              Linked enrolment, outpatient encounter, pharmacy and procedural billing                                                                        USA           2001 to 2004                    39 months             
  Curtis *et al* [@R43]              Unidentified administrative claims                                                                                                             USA           1998 to 2005                    3 years               6/6
  Curtis *et al* [@R44]              Unidentified administrative claims                                                                                                             USA           1998 to 2005                    3 years               6/6
  Curtis *et al* [@R45]              Unidentified administrative claims                                                                                                             USA           1998 to 2005                    1 year                6/6
  Devine *et al* [@R46]              Pharmacy data transaction service data warehouse                                                                                               USA           2006 to 2008                    1 year                8/8
  Devold *et al* [@R47]              Norwegian prescription database                                                                                                                Norway        2005 to 2009                    5 years               8/8
  Downey *et al* [@R24]              National administrative claims                                                                                                                 USA           2001 to 2003                    1 year                6/6
  Dugard *et al* [@R48]              An unidentified database of GP records                                                                                                         UK            1996 to 2002                    5 years               6/6
  Ettinger *et al* [@R49]            A large database was accessed through                                                                                                          USA           2002 to 2003                    1 year                6/6
  Feldstein *et al* [@R50]           Undefined health maintenance organisation                                                                                                      USA           1996 to 2006                    2.7 years             6/6
  Gallagher *et al* [@R51]           General practice research database                                                                                                             UK            1987 to 2006                    2.3 years             8/8
  Gold *et al* [@R52]                IMS longitudinal prescription                                                                                                                  USA           X to 2005                       6 months              8/8
  Gold *et al* [@R53]                Unidentified pharmacy claims                                                                                                                   USA           1996 to 2003                    2 years               6/6
  Gold *et al* [@R54]                IMS longitudinal prescription                                                                                                                  USA           1996 to 2003                    1 year                8/8
  Hadji *et al* [@R55]               IMS disease analyser patient                                                                                                                   Germany       2004 to 2007                    2 years               6/6
  Hadji *et al* [@R25]               Techniker krankenkasse                                                                                                                         Germany       2006 to 2009                    2 years               6/6
  Hadji *et al* [@R56]               IMS disease analyser patient                                                                                                                   Germany       2001 to 2010                    1 year                6/6
  Halpern *et al* [@R26]             Unidentified administrative claims                                                                                                             USA           2002 to 2006                    18 months             8/8
  Hansen *et al* [@R27]              Danish national registers                                                                                                                      Denmark       1996 to 2006                    5.2 years             6/6
  Hansen *et al* [@R57]              Veteran affairs pharmacy service records                                                                                                       USA           2000 to 2004                    2 years               8/8
  Hawley *et al* [@R58]              Sistema d'informaciό per al desenvolupament de l'investigaciό en atenciό primaria                                                              Spain         2006 to 2007                    6 months              6/6
  Hoer *et al* [@R59]                Claims database of a statutory sickness fund                                                                                                   Germany       2000 to 2004                    2 years               6/6
  Ideguchi *et al* [@R60]            Yokohama City University Medical Centre                                                                                                        Japan         2000 to 2005                    5 years               6/6
  Iolascon *et al* [@R28]            Unidentified administrative prescription database campania                                                                                     Italy         2008 to 2010                    1 year                6/6
  Jones *et al* [@R61]               Ontario Drugs Database and Brogan Inc. private payer database                                                                                  Canada        2003 to 2006                    1 year                6/6
  Kamatari *et al* [@R62]            Pharmacy prescription database                                                                                                                 Japan         2000 to 2005                    4 years               6/6
  Kertes *et al* [@R63]              Maccabi healthcare services database                                                                                                           Israel        2003 to 2004                    1 year                6/6
  Kishimoto and Machara[@R64]        Platform for clinical information statistical analysis database                                                                                Japan         2006 to 2014                    8 years               6/6
  Lakatos *et al* [@R65]             National health insurance fund administration                                                                                                  Hungary       2004 to 2013                    2 years               6/6
  Landfeldt *et al* [@R66]           Swedish prescribed drug register                                                                                                               Sweden        2005 to 2009                    4 years               6/6
  LeBlanc *et al* [@R67]             Kaiser Permanente Northwest                                                                                                                    USA           1997 to 2011                    5 years               6/6
  Li *et al* [@R68]                  General practice research database                                                                                                             UK            1995 to 2008                    5 years               6/6
  Lin *et al* [@R69]                 Unidentified health insurance database                                                                                                         Taiwan        2003 to 2006                    1 year                6/6
  Lo *et al* [@R70]                  Kaiser Permanente of Northern California                                                                                                       USA           2002 to 2004                    1 year                8/8
  Martin *et al* [@R71]              HealthCore integrated research database                                                                                                                      2005 to 2007                    3 years               8/8
  McCombs *et al* [@R72]             Unidentified health insurance company, California                                                                                              USA           1998 to 2001                    1 year                6/6
  Modi *et al* [@R73]                InVision data mart database                                                                                                                    USA           2002 to 2009                    1 year                6/6
  Modi *et al* [@R74]                InVision data mart database                                                                                                                    USA           2001 to 2010                    2 years               6/6
  Modi *et al* [@R75]                Humana administrative health claims database                                                                                                   USA           2007 to 2013                    1 year                6/6
  Netelenbos *et al* [@R76]          IMS health longitudinal prescription database                                                                                                  Netherlands   2007 to 2008                    1 year                6/6
  Olsen *et al* [@R77]               The Danish national prescription register                                                                                                      Denmark       1997 to 2006                    2 years               8/8
  Papaioannou *et al* [@R78]         The Canadian database of osteoporosis and osteopenia                                                                                           Canada        1990 to 2001                    3 years               8/8
  Patrick *et al* [@R79]             Medicare and the Pennsylvania pharmaceutical assistance contract for the elderly                                                               USA           1996 to 2005                    6 months              6/6
  Penning-van Beest *et al* [@R80]   PHARMO record linkage system                                                                                                                   Netherlands   2000 to 2003                    1 year                6/6
  Penning-van Beest *et al* [@R81]   PHARMO record linkage system                                                                                                                   Netherlands   1999 to 2004                    1 year                6/6
  Penning-van Beest *et al* [@R82]   PHARMO record linkage system database                                                                                                          Netherlands   1999 to 2004                    1 year                8/8
  Rabenda *et al* [@R83]             Belgian national social security institute                                                                                                     Belgium       2001 to 2004                    1 year                8/8
  Recker *et al* [@R84]              NDC health database                                                                                                                            USA           2002 to 2003                    1 year                6/6
  Reynolds *et al* [@R85]            Kaiser Permanente Southern California                                                                                                          USA           2009 to 2011                    1 year                6/6
  Richards *et al* [@R86]            Veterans affairs rheumatoid arthritis registry                                                                                                 USA                                           39.2 months           8/8
  Rietbrock *et al* [@R87]           General practice research database                                                                                                             UK                                            1 year                6/6
  Roerholt *et al* [@R88]            National hospital discharge register and Danish national prescriptions database, Denmark                                                       Denmark       1997 to 2004                    9 years               6/6
  Roughead *et al* [@R89]            Department of veterans' affairs                                                                                                                Australia     2001 to 2007                                          6/6
  Sampalis *et al* [@R90]            Ontario ministry of health and long-term care databases                                                                                        Canada        1996 to 2009                    14 years              6/6
  Scotti *et al* [@R91]              Healthcare utilisation databases, Lombardy                                                                                                     Italy         2003 to 2010                    5.3 years             8/8
  Sheehy *et al* [@R92]              Régie de l'assurance maladie du Québec databases                                                                                                             2002 to 2007                    1 year                6/6
  Siris *et al* [@R93]               MedStat MarketScan commercial claims and encounters and Medicare databases                                                                     USA           1999 to 2003                    2 years               6/6
  Siris *et al* [@R94]               The MarketScan commercial claims and encounters and Medicare supplemental and coordinator of benefits databases                                USA           2001 to 2008                    2.4 years             6/6
  Soong *et al* [@R95]               National health insurance research database                                                                                                    Taiwan        2004 to 2006                    1 year                6/6
  Ström[@R96]                        Swedish prescribed drug register                                                                                                               Sweden        2005 to 2009                    4 years               6/6
  Sunyecz *et al* [@R97]             Thomson healthcare, MarketScan commercial claims and encounters and MarketScan Medicare, supplemental and coordination of benefits databases   USA           2000 to 2002                    3 years               6/6
  Tafaro *et al* [@R98]              General practitioner databases                                                                                                                 Italy         2001 to 2007                    300 days              6/6
  Van Boven *et al* [@R99]           The InterAction database                                                                                                                       Netherlands   2003 to 2011                    1 year                6/6
  Van den Boogaard *et al* [@R100]   PHARMO record linkage system                                                                                                                   Netherlands   1996 to 2003                    3 years               6/6
  Wang *et al* [@R101]               Centres for Medicare and Medicaid services                                                                                                     USA           2006 to 2010                    5 years               6/6
  Weiss *et al* [@R102]              IMS longitudinal prescription database                                                                                                                       2004 to 2006                    1 year                6/6
  Weycker *et al* [@R103]            PharMetrics patient-centric database                                                                                                           USA           1998 to 2003                    5.5 years             6/6
  Weycker *et al* [@R104]            Health alliance plan of Henry Ford Health System                                                                                               USA           2002 to 2007                    27.1 months           6/6
  Yeaw *et al* [@R105]               PharMetrics patient-centric database                                                                                                           USA           2005 to 2005                    1 to 2 years          6/6
  Yood *et al* [@R106]               Unidentified health maintenance organisation                                                                                                   USA           1998 to 1999                    18 months             6/6
  Zambon *et al* [@R107]             Health services databases of Lombardy                                                                                                          Italy         2003 to 2005                    3 years               6/6
  Ziller *et al* [@R108]             IMS longitudinal prescription database                                                                                                         Germany       2007 to 2009                    1 year                6/6

GP, general practitioner; NOS, Newcastle--Ottawa quality assessment scale; N/A, not reported.

The geographical location of the studies included were: USA (n=37), Canada (n=7), UK (n=6), Netherlands (n=6), Denmark (n=5), Italy (n=5), Germany (n=5), Japan (n=3), Taiwan (n=3), Spain (n=2), France (n=2) and single studies from Singapore, Norway, Israel, Hungary, Sweden, Belgium and Australia (see [table 1](#T1){ref-type="table"}). The mean age of patients included within the studies ranged between 53 to 80.8 years and the length of follow-up ranges between 3 months and 14 years. The length of follow-up of the included studies could be stratified to 6 months (n=4), 1 year (n=37), 2 years (n=16) and ≥3 years (n=32).

The medications included in this review as primary or secondary prevention in the treatment of osteoporosis are alendronate, etidronate, risedronate, ibandronate, clodronate, zoledronate, alendronate +vitamin D and risedronate +calcium. Some of the included studies also looked at pamidronate and raloxifene.[@R20] In order to measure the persistence and adherence of patients to these medications the included studies have used different techniques.[@R20] Persistence was measured based on the length of treatment without a gap in refills ([table 2](#T2){ref-type="table"}). The permissible gap between medication refills the included studies used was typically 30 days, and sometime 60 or 90 days. On the other hand, adherence was measured by calculating the medication possession ratio (MPR),[@R20] and proportion of days covered (PDC).[@R21] MPR means the number of days' supply of medication received divided by the length of the follow-up period.[@R109]

###### 

Persistence data for osteoporosis medications by study

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                          Medications                                         Population (mean age)   Length of persistence (days)                                        Patient persistence                                                                                                                                                             
  ---------------------------------- --------------------------------------------------- ----------------------- ------------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Brankin *et al* [@R31]             Alendronate, risedronate                            15 330 (71.7)           233                                                                 n/a                                                            55% (weekly regimen), 42.8% (daily regimen)                                                                      n/a

  Burden *et al* [@R34]              Alendronate, etidronate, risedronate                451 113 (75.6)          n/a                                                                 n/a                                                            63.10%                                                                                                           46.40%

  Burden *et al* [@R35]              Alendronate, etidronate, risedronate                337 329 (75.7)          n/a                                                                 n/a                                                            56%\*, 66%†                                                                                                      n/a

  Carbonell-Abella *et al* [@R22]    Alendronate, ibandronate, risedronate               118 829 (66.9)          n/a                                                                 n/a                                                            14.1% (alendronate daily), 56.5% (alendronate weekly), 35.8% (ibandronate monthly), 7.7% (risedronate daily),\   n/a
                                                                                                                                                                                                                                                    31.2% (risedronate weekly), 40.0% (risedronate monthly)                                                          

  Cheen *et al* [@R36]               Alendronate, risedronate                            798 (68.5)              n/a                                                                 n/a                                                            69%\*                                                                                                            n/a

  Cheng *et al* [@R23]               Alendronate                                         1745 (68.1)             n/a                                                                 n/a                                                            57.1%\*                                                                                                          41.8%\*

  Cotté *et al* [@R39]               Alendronate, risedronate                            2990 (69.9)             169                                                                 45.7%\*                                                        30.4%\*                                                                                                          n/a

  Cramer *et al* [@R40]              Alendronate, risedronate, ibandronate               2741 (n/a)              196                                                                 44.6%\* (daily), 58.1%\* (weekly)                              31.7%\* (daily), 44.2%\* (weekly)                                                                                n/a

  Cramer *et al* [@R41]              Alendronate, risedronate                            2741 (73)               204                                                                 n/a                                                            50%‡ (weekly), 38.6%‡ (daily)                                                                                    n/a

  Curtis *et al* [@R42]              Alendronate, risedronate                            1158 (53)               n/a                                                                 51.4%§ (alendronate)\                                          32.4%§(alendronate), 26.7%b (risedronate)                                                                        9.5%§ (alendronate), 5.4%§ (risedronate)
                                                                                                                                                                                     46.8%§ (risedronate)                                                                                                                                                            

  Devine *et al* [@R46]              Alendronate, ibandronate,\                          22 363 (n/a)            189.8\* (weekly), 196.3\* (monthly)                                 n/a                                                            n/a                                                                                                              n/a
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Downey *et al* [@R24]              Alendronate, risedronate                            10 566 (66.4)           n/a                                                                 n/a                                                            21.3% (alendronate), 19.4% (risedronate)                                                                         n/a

  Dugard *et al* [@R48]              Not stated                                          254 (76.7)              n/a                                                                 n/a                                                            74%¶                                                                                                             59%¶

  Ettinger *et al* [@R49]            Alendronate, risedronate                            211 319 (n/a)           n/a                                                                 n/a                                                            56.7%\* (weekly), 39%\* (daily)                                                                                  n/a

  Gallagher *et al* [@R51]           Alendronate, risedronate                            44 531 (n/a)            n/a                                                                 n/a                                                            58.3%§                                                                                                           n/a

  Gold *et al* [@R52]                Ibandronate, risedronate                            234 862 (n/a)           144.3§ (risedronate),\                                              29%§ (ibandronate)\                                            n/a                                                                                                              n/a
                                                                                                                 100.1§ (ibandronate)                                                56%§(risedronate)                                                                                                                                                               

  Gold *et al* [@R53]                Alendronate                                         4769 (n/a)              261\*                                                               38%\* (daily), 49%\* (weekly)                                  26%\* (daily), 36%\* (weekly)                                                                                    16%\* (daily), 24%\* (weekly)

  Gold *et al* [@R54]                Ibandronate, risedronate                            263 383 (66.21)         151.54§ (bandronate)\                                               n/a                                                            18.4%§ (ibandronate), 40%**§** (risedronate)                                                                     n/a
                                                                                                                 250.04§ (risedronate)                                                                                                                                                                                                                               

  Hadji *et al* [@R55]               Alendronate, clodronate,\                           4147 (n/a)              145.5\*                                                             n/a                                                            27.9%\*                                                                                                          12.9%\*
                                     etidronate, risedronate                                                                                                                                                                                                                                                                                                         

  Hadji *et al* [@R25]               Alendronate, clodronate,\                           19 752 (n/a)            n/a                                                                 n/a                                                            26%\*                                                                                                            20.1%\*
                                     etidronate, risedronate                                                                                                                                                                                                                                                                                                         

  Hadji *et al* [@R56]               Clodronate, ibandronate,\                           280 (63.2)              n/a                                                                 n/a                                                            45.6%§                                                                                                           n/a
                                     pamidronate, zoledronate                                                                                                                                                                                                                                                                                                        

  Hansen *et al* [@R27]              Alendronate, other oral bisphosphonates             100 556 (70.4)          1463\*\* (alendronate)\                                             n/a                                                            n/a                                                                                                              n/a
                                                                                                                 532.9\*\* (clodronate)\                                                                                                                                                                                                                             
                                                                                                                 963.6\*\* (etidronate)\                                                                                                                                                                                                                             
                                                                                                                 1408.9\*\* (ibandronate)\                                                                                                                                                                                                                           
                                                                                                                 1018\*\* (risedronate)                                                                                                                                                                                                                              

  Hansen *et al* [@R57]              Alendronate                                         198 (71)                n/a                                                                 n/a                                                            n/a                                                                                                              28%

  Hawley *et al* [@R58]              Not stated                                          21 385 (n/a)            n/a                                                                 45.65%                                                         n/a                                                                                                              n/a

  Hoer *et al* [@R59]                Alendronate, etidronate,\                           4451 (n/a)              n/a                                                                 71.3%\*                                                        47.3%\*                                                                                                          14.5%\*
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Ideguchi *et al* [@R60]            Alendronate, etidronate,\                           1307 (61.3)             n/a                                                                 n/a                                                            74.8%§                                                                                                           60.6%§
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Iolascon *et al* [@R28]            Alendronate, risedronate,\                          18 515 (68.9)           n/a                                                                 n/a                                                            12.6%\* (alendronate), 15.8%\* (risedronate), 21.6%\* (ibandronate)                                              n/a
                                     ibandronate                                                                                                                                                                                                                                                                                                                     

  Jones *et al* [@R61]               Alendronate, risedronate,                           62 897 (n/a)            n/a                                                                 72%\* (alendronate weekly)\                                    56.3%\* (alendronate weekly), 54.4%\* (risedronate weekly)                                                       n/a
                                                                                                                                                                                     71.2%\* (risedronate weekly)                                                                                                                                                    

  Kamatari *et al* [@R62]            Alendronate, risedronate                            1274 (74)               n/a                                                                 n/a                                                            42.5% \* (alendronate),44.6% \* (risedronate)                                                                    n/a

  Kertes *et al* [@R63]              Alendronate, risedronate                            4448 (n/a)              216\*                                                               n/a                                                            46%\*                                                                                                            n/a

  Kishimoto and Machara[@R64]        Not stated                                          12 230 (59.8)           n/a                                                                 n/a                                                            33.2%\* (daily regimen)                                                                                          13.0%\* (daily), 32.7%\* (weekly), 50.4%\* (weekly regimen)

  Lakatos *et al* [@R65]             Alendronate, risedronate, ibandronate               296 300 (68.3)          n/a                                                                 50%†† (alendronate), 50% †† (ibandronate),\                    35% †† (alendronate), 30% ††(ibandronate), 42% ††(risedronate)                                                   20%††† (alendronate), 16% ††† (ibandronate),\
                                                                                                                                                                                     55% †† (risedronate)                                                                                                                                                            22% ††† (risedronate)

  Landfeldt *et al* [@R66]           Alendronate, risedronate                            56 586 (71)             n/a                                                                 n/a                                                            55%†† (alendronate), 54% †† (risedronate)                                                                        38%†† (alendronate), 38%†† (risedronate)

  LeBlanc *et al* [@R67]             Not stated                                          14 674 (71)             n/a                                                                 n/a                                                            58%¶¶                                                                                                            23%‡‡

  Li *et al* [@R68]                  Alendronate, etidronate, risedronate, ibandronate   66 116 (71.4)           n/a                                                                 27%\* (alendronate daily), 52.8%\* (alendronate weekly),\      17.6%\* (alendronate daily), 41.3%\* (alendronate weekly), 6.5%\* (ibandronate monthly),\                        n/a
                                                                                                                                                                                     56.8%\* (Ibandronate monthly), 37.8%\* (risedronate daily),\   26.4%\* (risedronate daily), 41.1%\* (risedronate weekly)                                                        
                                                                                                                                                                                     53.1%\* (risedronate weekly)                                                                                                                                                    

  Lo *et al* [@R70]                  Alendronate                                         13 455 (68.8)           378†                                                                40%†                                                           50%†                                                                                                             n/a

  McCombs *et al* [@R72]             Alendronate, etidronate,\                           3720 (69.1)             170                                                                 n/a                                                            n/a                                                                                                              n/a
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Modi *et al* [@R73]                Alendronate, etidronate,\                           75 593 (64.4)           115.6\*                                                             39.30%\*                                                       n/a                                                                                                              n/a
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Netelenbos *et al* [@R76]          Alendronate, etidronate, ibandronate,\              105 506 (69.2)          n/a                                                                 43.10%§§                                                       n/a                                                                                                              n/a
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Papaioannou *et al* [@R78]         Alendronate, etidronate                             1673 (66.8)             n/a                                                                 n/a                                                            77.6% (alendronate), 90.3% (etidronate)                                                                          70.1% (alendronate), 80.5% (etidronate)

  Penning-van Beest *et al* [@R80]   Alendronate, risedronate                            2124 (71.6)             n/a                                                                 n/a                                                            42.9%\*                                                                                                          n/a

  Rabenda *et al* [@R83]             Alendronate                                         54 807 (n/a)            n/a                                                                 58%¶¶                                                          40%¶¶                                                                                                            n/a

  Richards *et al* [@R86]            Alendronate, risedronate                            573 (68.7)              1176**§**                                                                                                                          n/a                                                                                                              n/a

  Rietbrock *et al* [@R87]           Alendronate, risedronate                            44 531 (71)             n/a                                                                 n/a                                                            58.30%                                                                                                           n/a

  Roerholt *et al* [@R88]            Alendronate, etidronate, ibandronate                6210 (74.7)             474 (alendronate 10 mg),\                                           n/a                                                            n/a                                                                                                              n/a
                                                                                                                 1350.5 (alendronate 70 mg),\                                                                                                                                                                                                                        
                                                                                                                 803 (etidronate)                                                                                                                                                                                                                                    

  Roughead *et al* [@R89]            Not stated                                          42 885 (80.8)                                                                               n/a                                                            n/a                                                                                                              n/a

  Sampalis *et al* [@R90]            Alendronate, ibandronate,\                          636 114 (72)            n/a                                                                 41.0%\*                                                        41.0%\*                                                                                                          26.6%\*
                                     Risedronate                                                                                                                                                                                                                                                                                                                     

  Sheehy *et al* [@R92]              Alendronate                                         32 804 (n/a)            n/a                                                                 79% \*\*\*                                                     65%\*\*\*                                                                                                        n/a\*\*\*

  Siris *et al* [@R93]               Alendronate, risedronate                            35 357 (65.3)           n/a                                                                 n/a                                                            n/a                                                                                                              20%\*

  Soong *et al* [@R95]               Alendronate                                         32 604 (72.4)           n/a                                                                 48.03%\*                                                       17.6%\*                                                                                                          n/a

  Ström[@R96]                        Alendronate, risedronate                            36 433 (70.2)           n/a                                                                 n/a                                                            51.67%††                                                                                                         n/a

  Sunyecz *et al* [@R97]             Alendronate, risedronate                            32 944 (64.3)           n/a                                                                 n/a                                                            n/a                                                                                                              21%\*(3 years)

  Van Boven *et al* [@R99]           Alendronate, etidronate,\                           8610 (67.5)             n/a                                                                 n/a                                                            48.9%\*                                                                                                          40%\*(3 years)
                                     Ibandronate, risedronate                                                                                                                                                                                                                                                                                                        

  Van den Boogaard *et al* [@R100]   Alendronate, etidronate,\                           14 760 (n/a)            n/a                                                                 n/a                                                            43.60%                                                                                                           27.40%
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Weiss *et al* [@R102]              Alendronate, ibandronate,\                          165 955 (67.1)          109\*                                                               n/a                                                            n/a                                                                                                              n/a
                                     risedronate                                                                                                                                                                                                                                                                                                                     

  Weycker *et al* [@R103]            Alendronate, risedronate                            18 822 (62.2)           n/a                                                                 45.5%§(daily),47.3% § (weekly)                                 19.2%§ (daily)                                                                                                   3.7%§ (daily), 3.6%§(weekly)

  Yeaw *et al* [@R105]               Alendronate, ibandronate,\                          10 268 (56.9)           n/a                                                                 56%\*                                                          41%†                                                                                                             n/a
                                     risedronate, zoledronate, etidronate, pamidronate                                                                                                                                                                                                                                                                               

  Ziller *et al* [@R108]             Alendronate, etidronate, risedronate                268 568 (63.3)          239.8 hour (alendronate 70 mg), 218.7§ (alendronate +vitamin D),\   n/a                                                            44.8% hour (alendronate 70 mg), 37.8%h (alendronate +vitamin D),\                                                n/a
                                                                                                                 246.4§ (etidronate), 256.4§ (ibandronate 150mg),\                                                                                  43.4%h (etidronate), 50.8%h (ibandronate), 30.3%h (residronate)                                                  
                                                                                                                 190.9§ (residronate)                                                                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Persistence with no refill gaps ≥ 30 days.

†Persistence with no refill gabs \> 60 days.

‡Patient persistence defined as length of time before a refill gap \> 30 days.

§Persistence with no refill gaps ≥ 90 days.

¶Persistence was defined as complete cessation or a gap \> 12 months.

\*\* Persistence with as no refill gaps \> 56 days/8 weeks, n/a means not reported.

††Persistence with no refill gaps \> 8 weeks.

‡‡Persistence was defined as the length of time until a refill gap \> 3 months.

§§Persistence with no refill gaps \> 6 months, n/a means not reported.

¶¶Persistence was defined as length of time without a refill gap \> 5 weeks.

\*\*\*Persistence was defined as length of time until refill gap exceeding 1.5 x prescription length, n/a means not reported.

Persistence {#s3a}
-----------

Sixty studies assessing persistence using real-world data from 4 070 739 patients were identified ([table 2](#T2){ref-type="table"}). The overall mean persistence of oral bisphosphonates at 6 months,[@R39] 1 year,[@R21] 2 years[@R25] and 3 years ranged from 34.8% to 71.3%, 17.65% to 74.80%, 12.9% to 60.60% and 21.0% to 40.0% respectively ([figure 2](#F2){ref-type="fig"}). The 6 month persistence of ibandronate,[@R39] alendronate[@R42] and risedronate,[@R39] ranged from 29% to 57.3%, 45.5% to 79% and 46.8% to 77%, respectively. Thirteen studies reported 1 year persistence data for alendronate (12.6% to 70.1%),[@R22] risedronate (15.8% to 68.0%)[@R22] and ibandronate (18.4% to 58.5%)%).[@R22]

Out of 19 studies,[@R25] that reported the 2 year persistence of oral bisphosphonates, more than 70% of them found the proportion of patients persistent to be \<30%. A 3 year persistence of 21% and 40% was reported by two studies.[@R97]

![Frequency for reported range of mean persistence per length of treatment.](bmjopen-2018-027049f02){#F2}

Adherence {#s3b}
---------

We identified 55 studies that measured adherence based on real-world data from 4 033 731 patients in different countries ([table 3](#T3){ref-type="table"}). The minimum length of follow-up period used in the included studies to measure MPR and PDC was 3 months. The 3 month follow-up study reported the proportion of adherent patients to alendronate and risedronate as 72.8% (daily) and 80% (weekly).[@R80] Few studies reported MPR that ranged between 55.6% and 90% for 6 months follow-up ([table 3](#T3){ref-type="table"}).[@R21] Across all studies that reported MPR at 1 year, the proportion of patients adherent to medication varied from 31.7% to 72.0%.[@R23]

###### 

Adherence data for osteoporosis medications

  Reference                          Medication                                          Population (mean age)   Compliance, mean MPR                                                                                 
  ---------------------------------- --------------------------------------------------- ----------------------- ------------------------------------------------------------------ --------------------------------- --------------------------------------
  Abrahamsen[@R29]                   Alendronate                                         58 674 (n/a)            \<5 years                                                          5 to 10 years                     \>10 years
                                     Etidronate                                                                  Alendronate (92%)                                                  Alendronate (84%)                 Alendronate (76%)
                                     Ibandronate                                                                 Etidronate (92%)                                                   Etidronate (89%)                  Etidronate (88%)
                                     Risedronate                                                                 Ibandronate (81%)                                                  Ibandronate (75%)                 Ibandronate (70%)
                                     Clodronate                                                                  Risedronate (91%)                                                  Risedronate (80%)                 Risedronate (75%)
  Blouin *et al* [@R20]              Alendronate                                         15 027 (76.6)           69.7%±34.8%                                                                                          
                                     Risedronate                                                                                                                                                                      
  Briesacher *et al* [@R32]          Alendronate, risedronate                            17 988 (61.4)           At 1 year,                                                         At 2 years,                       At 3 years,
                                                                                                                 42.9% (MPR ≥80%)                                                   34.5% (MPR ≥80%)                  30.6% (MPR ≥80%)
                                                                                                                 12.6% (MPR 60% to 79%)                                             10% (MPR 60% to 79%)              10% (MPR 60% to 79%)
                                                                                                                 10.4% (MPR 40% to 59%)                                             7.7% (MPR 40% to 59%)             7.2% (MPR 40% to 59%)
                                                                                                                 13.8% (MPR 20% to 39%)                                             8.2% (MPR 20% to 39%)             7.8% (MPR 20% to 39%)
                                                                                                                 20.4% (MPR \<20%)                                                  38.7% (MPR \<20%)                 44.2% (MPR \<20%)
  Briesacher *et al* [@R33]          Alendronate, ibandronate, risedronate               61 125 (62.1)           At 1 year (monthly medication),                                    At 1 year (weekly medications)    At 1 year (daily medication)
                                                                                                                 49% (MPR≥80%)                                                      49% (MPR ≥80%)                    23% (MPR ≥80%)
                                                                                                                 11% (MPR 60% to 79%), 11% (MPR 40% to 59%), 13% (MPR 20% to 39%)   14% (MPR 60% to 79%)              8% (MPR 60% to 79%)
                                                                                                                 16% (MPR \<20%)                                                    9% (MPR 40% to 59%)               11% (MPR 40% to 59%)
                                                                                                                                                                                    14% (MPR 20% to 39%)              16% (MPR 20% to 39%)
                                                                                                                                                                                    14% (MPR \<20%)                   42% (MPR \<20%)
  Burden *et al* [@R35]              Alendronate, etidronate, risedronate                337 329 (75.7)          70%[\*](#tblfn13){ref-type="fn"}                                                                     
  Cadarette *et al* [@R21]           Alendronate, risedronate                            20 205 (79)             49.8% (PDC ≥80%); 14.5% (PDC 51% to 79%); 35.7% (PDC ≤50%)                                           
  Cheen *et al* [@R36]               Alendronate, risedronate                            798 (68.5)              78.90%                                                                                               
  Cheng *et al* [@R23]               Alendronate                                         1745 (68.1)             At 1 year; 61.9%                                                   At 2 years, 47.9% (MPR ≥80%)      
                                                                                                                 (MPR \>80%)                                                                                          
  Colombo and Montecucco[@R37]       Generic alendronate, branded alendronate            20 711 (73)             69% to 74%                                                                                           
  Copher *et al* [@R38]              Alendronate, ibandronate, risedronate               1587 (62.3)             48.70% (95% CI 46.2 to 51.2)                                                                         
  Cotté *et al* [@R39]               Alendronate, risedronate                            2990 (69.9)             79.4% (95% CI 78.2 to 80.5) (weekly medications)                                                     
                                     Ibandronate                                                                 84.5% (95% CI 83.1 to 85.9) (monthly ibandronate)                                                    
  Cramer *et al* [@R40]              Alendronate, risedronate, ibandronate               2741 (n/a)              60.60%                                                                                               
  Cramer *et al* [@R41]              Alendronate, risedronate                            2741(73)                64%                                                                                                  
  Curtis *et al* [@R42]              Alendronate, risedronate                            1158 (53)               73%                                                                                                  
  Curtis *et al* [@R43]              Alendronate, risedronate                            25 446 (n/a)            At 2 years,                                                                                          At 3 years,
                                                                                                                 Achieved MPR \>80% = 29.4%                                                                           Achieved MPR \>80% = 27.2%
                                                                                                                 Achieved MPR \<50% = 34.9%                                                                           Achieved MPR \<50% = 39.4%
  Curtis *et al* [@R45]              Alendronate                                         101 038 (n/a)           Achieving MPR \>80% = 44%                                                                            
                                     Ibandronate, risedronate                                                                                                                                                         
  Devine *et al* [@R46]              Alendronate, ibandronate, risedronate               22 363 (n/a)            62%                                                                                                  
  Devold *et al* [@R47]              Alendronate                                         7610 (66.6)             Achieving MPR ≥80% = 45.5%                                                                           
  Downey *et al* [@R24]              Alendronate, risedronate                            10 566 (66.4)           60.7% (alendronate)                                                                                  
                                                                                                                 58.4% (risedronate)                                                                                  
  Dugard *et al* [@R48]              Not stated                                          254 (76.7)              At 1 year,                                                         At 3 years,                       At 5 years, achieving MPR ≥80% = 23%
                                                                                                                 Achieving MPR ≥80% = 44%                                           Achieving MPR ≥80% = 42%          
  Feldstein *et al* [@R50]           Alendronate, ibandronate, risedronate               1829 (72)               60%                                                                                                  
  Gold *et al* [@R52]                Ibandronate, risedronate                            234 862 (n/a)           83.3% (risedronate)                                                79% (risedronate)                 
                                                                                                                 78.5% (ibandronate)                                                                                  
  Gold *et al* [@R53]                Ibandronate, risedronate                            263 383 (66.21)         74.68% (ibandronate)                                                                                 
                                                                                                                 80.15% (risedronate)                                                                                 
  Hadji *et al* [@R55]               Alendronate, clodronate, etidronate, risedronate    4147 (n/a)              Achieving MPR ≥80% = 66.3%                                                                           
                                                                                                                 Achieving MPR \<80% = 22.7%                                                                          
  Halpern *et al* [@R26]             Alendronate, ibandronate, risedronate               21 655 (63.3)           At 6 months,                                                                                         At 18 months,
                                                                                                                 76% (commercially insured)                                                                           59% (commercially insured)
                                                                                                                 68% (Medicare advantage)                                                                             53% (Medicare advantage)
  Hansen *et al* [@R57]              Alendronate                                         198 (71)                At 12 months,                                                                                        At 2 years,
                                                                                                                 Achieving MPR ≥80% = 59%                                                                             Achieving MPR ≥80% = 54%
  Hoer *et al* [@R59]                Alendronate, etidronate, risedronate                4451(n/a)               At 6 months,                                                                                         At 1 year,
                                                                                                                 Achieving MPR ≥80% = 58.6%                                                                           Achieving MPR ≥80% = 46.25%
  Kishimoto and Machara[@R64]        Not stated                                          12 230 (62)             At 1 year,                                                                                           At 5 years,
                                                                                                                 38.6% (daily)                                                                                        20.8% (daily)
                                                                                                                 70.6% (weekly)                                                                                       60.9% (weekly)
                                                                                                                 77.7% (monthly)                                                                                      
  LeBlanc *et al* [@R67]             Not stated                                          14 674 (71)             94%                                                                                                  
  Lin *et al* [@R69]                 Alendronate                                         8936 (74)               60.20%                                                                                               
  Lo *et al* [@R70]                  Alendronate                                         13 455 (68.8)           93%                                                                                                  
  Martin *et al* [@R71]              Alendronate, ibandronate, risedronate               45 939 (59.6)           At 1 year,                                                         At 2 years,                       At 3 years,
                                                                                                                 58% (alendronate)                                                  48% (alendronate)                 42% (alendronate)
                                                                                                                 58% (ibandronate)                                                  50% (ibandronate)                 46% (ibandronate)
                                                                                                                 57% (isedronate)                                                   47% (risedronate)                 43% (risedronate)
  Modi *et al* [@R75]                Alendronate, ibandronate, risedronate               37 886 (74.1)           Achieving MPR ≥80% = 31.7%                                                                           
  Netelenbos *et al* [@R76]          Alendronate                                         105 506                 91%                                                                                                  
                                                                                         −69.2                                                                                                                        
  Olsen *et al* [@R77]               Alendronate, etidronate                             47 176 (70.3)           Achieving MPR \<50% = 28.4%                                                                          
                                                                                                                 Achieving MPR 50% to 79% = 11.8%                                                                     
                                                                                                                 Achieving MPR ≥80% = 59.8%                                                                           
  Penning-van Beest *et al* [@R81]   Alendronate, risedronate                            8822 (69.4)             At 3 months,                                                       At 6 months, achieving MPR ≥80%   At 1 year,
                                                                                                                 Achieving an MPR ≥80%                                              Daily = 60.3%                     Achieving MPR ≥80%,
                                                                                                                 Daily=72.8%                                                        Weekly = 70.8%                    Daily = 50.2%
                                                                                                                 Weekly=80.0%                                                                                         Weekly = 64.3%
  Penning-van Beest *et al* [@R82]   Alendronate, risedronate                            8822 (n/a)              Achieving MPR ≥80% = 58%                                                                             
  Rabenda *et al* [@R83]             Alendronate                                         54 807 (n/a)            64.70%                                                                                               
  Recker *et al* [@R84]              Alendronate, risedronate                            211 319 (n/a)           54% (daily regimen)                                                                                  
                                                                                                                 65% (weekly regimen)                                                                                 
  Richards *et al* [@R86]            Alendronate, risedronate                            573 (68.7)              69%                                                                                                  
  Sampalis *et al* [@R90]            Alendronate, ibandronate, risedronate               636 114 (72)            72%                                                                                                  
  Siris *et al* [@R93]               Alendronate, risedronate                            35 357 (65.3)           Achieving MPR ≥80% = 43%                                                                             
  Siris *et al* [@R94]               Alendronate, ibandronate, risedronate               460 584 (63.6)          53.50%                                                                                               
  Soong *et al* [@R95]               Alendronate                                         32 604 (72.44)          At 1 month,                                                        At 2 months,                      At 1 year,
                                                                                                                 Achieving MPR ≥80% = 87.6%                                         Achieving MPR ≥80% = 61.8%        Achieving MPR ≥80% = 28.2%
  Sunyecz *et al* [@R97]             Alendronate, risedronate                            32 944 (64.3)           55%                                                                                                  
  Tafaro *et al* [@R98]              Alendronate, clodronate, ibandronate, risedronate   6390 (n/a)              53% (daily regimen)                                                                                  
                                                                                                                 70% (weekly regimen)                                                                                 
  Wang *et al* [@R101]               Alendronate, ibandronate, risedronate               522 287 (n/a)           Achieving MPR \<33% = 41.1%                                                                          
                                                                                                                 Achieving MPR 34% to 65% = 21.5%                                                                     
                                                                                                                 Achieving MPR \>66% = 37.3%                                                                          
  Weycker *et al* [@R104]            Alendronate, ibandronate, risedronate               644 (65.9)              57%                                                                                                  
  Yeaw *et al* [@R105]               Alendronate                                         10 268 (56.9)           \*60%                                                                                                
                                     Ibandronate                                                                                                                                                                      
  Yood *et al* [@R106]               Alendronate, etidronate                             176 (63.3)              70.70%                                                                                               
  Ziller *et al* [@R108]             Alendronate                                         268 568 (63.3)          33% (alendronate 10 mg)                                                                              
                                                                                                                 57% (alendronate 70 mg)                                                                              

\*Mean Proportion of Days Covered (PDC).

MPR, medication possession ratio.

Across six studies adherence at 2 years was less than that of adherence at 1 year, ranging from 34.5% to 47.9%.[@R23] Parallel to this, six studies reported the proportion of patients who achieved MPR ≥80% at 3 years varied between 23% and 47.9%.[@R29] Overall, adherence rates to oral bisphosphonates reduced overtime within and across studies.

Determinants of persistence and adherence {#s3c}
-----------------------------------------

Out of the 89 studies, 55 reported at least one potential determinant of persistence and adherence to oral bisphosphonates (online [supplementary file 1](#SP1){ref-type="supplementary-material"}). The potential determinants of persistence and adherence reported in the studies included geographic residence,[@R30] prior bone mineral density (BMD) test,[@R20] chronic disease score,[@R30] hospitalisation,[@R30] medication type and frequency,[@R22] age,[@R27] history of fractures,[@R36] race/ethnicity[@R38] and number of co-medication.[@R40] In addition to these, glucocorticoid,[@R43] gender,[@R51] education status,[@R47] income,[@R47] marital status,[@R47] history of upper gastrointestinal problems,[@R51] tobacco use,[@R27] rheumatoid arthritis,[@R62] national insurance,[@R63] hormone replacement therapy,[@R70] clinical service use,[@R79] mental disorder,[@R104] diabetes and co-payments,[@R102] were mentioned as determinants of persistence and adherence. The relationship of these determinants to patients' persistence and adherence to medication is described below.
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In the studies that have reported prior BMD test as a determinant factor, patients who have undergone prior BMD test before receiving medications have higher persistence and adherence compared with those who have not.[@R20] Moreover, weekly oral bisphosphonates medication users had significantly higher mean persistence than those daily users.[@R22] Before decreasing at ages 80 and above a number of studies have reported higher persistence and adherence at older ages than younger ages.[@R27] Similarly, the number of co-medications being received at baseline was associated with a marginally greater risk of discontinuing.[@R40] Compared with male users of oral BP medications, female users were at lower odds of achieving adherence.[@R51]

Discussion {#s4}
==========

This review summarises patient persistence and adherence and their determinants with oral bisphosphonates in the treatment of osteoporosis in real-world settings. A total of 89 studies, undertaken in the USA, Canada, Europe, Asia and Australia were used to collect information on the real-world persistence and adherence with oral bisphosphonates for the treatment of osteoporosis. The analyses of these data suggest that patient persistence and adherence rates to oral bisphosphonates reduced over time following initial prescription. For example, the overall mean persistence of oral bisphosphonates at 6 months, 1 year and 2 years post-index ranged from 34.8% to 71.3%, 17.6% to 74.8% and 12.9% to 60.6%, respectively. Dosing frequency appeared to affect persistence, with 6 month persistence of oral bisphosphonates with daily, weekly and monthly medication ranging between 27% and 45.5%, 45.7% and 72% and 56.8% and 56.8%, respectively. The findings of this current review were similar to that reported by Cramer *et al* who found 1 year persistence to bisphosphonate therapy ranged between 17.9% to 78.0%.[@R16] The review by Cramer and colleagues also reported that patients prescribed weekly oral bisphosphonates exhibited better persistence than those prescribed daily oral bisphosphonates (35.7% to 69.7% vs 26.1% to 55.7%).

High adherence rates of oral bisphosphonates may also lead to the most effective way of improving the benefit of these medications. For example, evidence suggests that the 2 year probability of fracture in females with osteoporosis may only begin to decrease as MPR exceeds 50%, and notably so after it exceeds 75%.[@R93] Across all included studies that reported MPR at 6and 12 months, the proportion of patients adherent to medication varied from 31.7% to 72.0% and 55.6% to 90.0%, respectively. Mean medication possession ratio ranged from 0.59 to 0.81 (weekly) and 0.46 to 0.64 (daily), which are similar to the findings of a previous systematic review.[@R16]

Poor persistence and adherence to oral bisphosphonates, particularly in chronic asymptomatic disease such as osteoporosis, may compromise the clinical and economic effects of this class of medications among patients. In this review, 32 studies reported ≥50% persistence and adherence of alendronate, risedronate, etidronate and clodronate.[@R23] The remaining 57 studies reported ≤50% of persistence or adherence. The variation of patient persistence and adherence to medication across studies may be due to a number of factors and the healthcare system of the countries included within this review. Age[@R27] and medication dosing and frequency[@R22] as a determinant factor of osteoporosis was reported by 29 and 32 studies, respectively. The studies included also indicated that older patients were more likely to achieve higher persistence and adherence to oral bisphosphonates and that daily users of oral bisphosphonates medications have lower persistence and adherence than weekly users. Strengths and limitations to this review are acknowledged by the authors. This review involved a systematic and rigorous search for studies relating to patient persistence and adherence using real-world data. Measuring adherence and persistence based on real-world data is beneficial as it captures the timelines and frequency of refilling and thus measures the continuity of medication use.[@R110] Database-derived persistence and adherence assessment carries the advantage of being objective, quantifiable and simple.[@R111] Despite these strengths, it is also important to consider the following limitations. First, the calculation of persistence and adherence across the studies was heterogeneous. As a result, it was not possible to inferentially compare these studies with each other. Second, the calculation of persistence and adherence provided in the studies may not be true values. For example, billing and coding errors may occur because data for these studies were obtained from patients in unrestricted 'real world clinical settings' primarily for administrative purposes.[@R16] Collection and refilling of medication by patients does not guarantee that this medication was taken as directed, or at all. Third, although there are data for persistence and adherence of oral bisphosphonates from studies carried out from different geographical locations, it was not possible to identify any trends between the data and countries. Fourth, it is very difficult to capture the specific reasons for treatment discontinuation from prescription-driven or medical claim data rather than patient-derived data. The current review excluded data from randomised controlled trials to better reflect patient behaviour in the general osteoporosis population in real-life clinical practice. However, the exclusion of alternative designs such as open-label extension studies may infer an element of publication bias.

Additional studies are required to examine patient persistence or adherence in osteoporosis, including synthesis of qualitative studies to examine the reasons for discontinuation and real-world studies to examine healthcare resource use associated with osteoporosis medication in relation to adherence and persistence. As osteoporosis is a chronic disease, clinicians should not only take into consideration the efficacy and side effects of medications when deciding on treatment options, but also ensure that realistic patient expectations from treatment are set through patient education and counselling. The patient's lifestyle should also be considered as this is likely to impact adherence and persistence with osteoporosis therapy.

Conclusions {#s5}
===========

This review has summarised patient persistence and adherence to oral bisphosphonates from a quality assessed studies that have used real-world data. The findings of this review suggest that real-world patient persistence and adherence with oral bisphosphonates medications is often poor and drops notably over time following the initial prescription of oral medications. However, adherence and persistence tended to be better in older patients and in patients who were prescribed weekly, rather than daily medications. To maximise adherence and persistence to oral bisphosphonates, it is important to consider their possible determinants including medication type and frequency, hospitalisation, age, history of fractures, race/ethnicity, gender, educational status and income as this may help to improve the health outcomes of patients with osteoporosis.
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